Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

2860 - A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T>5cm), II, IIIA non-small cell lung cancer comparing S-1 versus S-1 with cisplatin


11 Sep 2017


Non-metastatic NSCLC and other thoracic malignancies


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Tatsuro Okamoto


Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381


T. Okamoto1, T. Yano2, M. Shimokawa3, S. Takeo4, K. Yamazaki4, K. Sugio5, M. Takenoyama6, A. Nagashima7, T. Tagawa1, Y. Emi8, Y. Maehara1

Author affiliations

  • 1 Department Of Surgery And Science, Kyushu University, Graduate School of Medical Sciences, 812-8582 - Fukuoka/JP
  • 2 Department Of Thoracic Surgery, National Hospital Organization Beppu Medical Center, Beppu/JP
  • 3 Clinical Research Institute, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 4 Department Of Thoracic Surgery And Clinical Research Institute, National Kyushu Medical Center Hospital, Fukuoka/JP
  • 5 Department Of Thoracic And Breast Surgery, Oita University, Faculty of Medicine, Yufu/JP
  • 6 Department Of Thoracic Oncology, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 7 Department Of Thoracic Surgery And Clinical Research Institute, Kitakyushu Municipal Medical Center, Kitakyushu/JP
  • 8 Department Of Surgery, Saiseikai Fukuoka General Hospital, 810 0001 - FUKUOKA/JP


Abstract 2860


Platinum-based combination chemotherapy is a standard postoperative adjuvant treatment for pathological stage II/III non-small cell lung cancer (NSCLC). Oral S-1 therapy has been demonstrated to have a good efficacy with less toxicity for advanced NSCLC treatment. S-1 might be also useful in the adjuvant setting for surgical NSCLC.


We performed a phase II randomized open label multi-institutional study in surgical patients with pathological stage IB (T > 5 cm), II or III NSCLC (7th TNM classification), who underwent complete resection from 2009 to 2013. One hundred and thirty-nine patients were randomly assigned to two arms: S-1 80mg/m2 oral, day1 to 14, q3w, 1year (arm A, n = 70) or S-1 80mg/m2 oral day1 to 21, q5w + cisplatin 60mg/m2 day8, q5w, 4 courses, followed by S-1 80mg/m2 oral day1 to 14, q3w, total 1year (arm B, n = 69). The primary endpoint was the disease free survival (DFS) rate at 2 years and was evaluated using Bayesian method. Either treatment arm would deserve further study if the Bayesian posterior probability that the 2-year DFS rate would exceed a value of 40% were more than 0.85. The secondary endpoints were overall survival (OS), safety, and feasibility.


The clinical characteristics of the patients were well balanced in terms of age, sex and pathological stage between the two arms. The DFS rate at 2 years was 51.4% (95% confidence interval [CI], 0.399–0.628) in arm A and 59.4% (95% CI, 0.476 – 0.702) in arm B. Both treatment arms met the primary endpoint: the probability of a DFS rate ≥ 40% at 2 years was over 0.97 in Arm and 1 in arm B. Neither DFS nor OS were significantly different (log-rank test; p = 0.1695 and p = 0.8684, respectively). No treatment-related deaths were observed in either treatment. The main G3/4 adverse events were appetite loss (arm A vs. arm B, 4.3% vs. 11.6%) and anemia (0% vs. 5.8%), which were not statistically different between the two arms. Treatment completion rate did not differ between the two arms (arm A vs. arm B: 45.7% [95% CI, 41.9–66.3%] vs. 43.5% [95% CI, 44.0–68.4%]).


Oral S-1 based adjuvant chemotherapy was feasible and promising for patients with completely resected NSCLC.

Clinical trial identification

UMIN000001765, 2009/03/12

Legal entity responsible for the study

academic group


Kyushu University Lung Surgery Study Group


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.